Advertisement

Topics

Cognition Therapeutics Inc. Company Profile

18:09 EDT 24th June 2018 | BioPortfolio

Cognition Therapeutics, Inc. is a leader in the discovery and development of small molecule therapeutics targeting the toxic proteins that cause the cognitive decline associated with Alzheimer's disease and other degenerative diseases of the human brain. Toxic proteins play a crucial role in a large class of diseases, and there are currently no therapeutics available to prevent or block the destructive effects of toxic oligomeric proteins. Cognition has leveraged its scientific expertise with these difficult targets to pioneer the use of proprietary assays that emphasize functional responses and proprietary medicinal chemistry that ensures novel, high quality small-molecule drug candidates for the treatment of these diseases.


News Articles [884 Associated News Articles listed on BioPortfolio]

Intense Exercise Fails to Boost Cognition in Dementia Patients

(MedPage Today) -- U.K. study shows better fitness, but not cognition

Cognition Therapeutics Co-Founder and CSO Susan Catalano to Present at the Annual ASENT Meeting

Pittsburgh, March 06, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alz...

Cognition Therapeutics to Participate in Leerink Partners 7th Annual Global Healthcare Conference

PITTSBURGH, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatmen...

Cognition Therapeutics Co-Founder and CSO Susan Catalano to Present at Sachs Neuroscience Innovation Forum

Pittsburgh, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of ...

Cognition Therapeutics Receives $6.6M in NIA Grants for Two Studies of Elayta™ to Expand Understanding of Synaptoprotective Mechanism of Action

PITTSBURGH, May 22, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer...

Cognition Therapeutics Presenting Evidence for Elayta Synaptic Protection in Alzheimer’s Patients at Combined AAT-AD/PD Focus Meeting

Pittsburgh, March 14, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment o...

Menopause and Cognition: A Matter of Timing?

In a British birth cohort, later versus earlier age at menopause differentially affected subsequent cognition.

Cognition Therapeutics Initiates NIA-Funded SNAP Study of Elayta™ to Measure Toxic Oligomer Displacement and Clearance in Alzheimer's Disease

Pittsburgh, June 05, 2018 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheime...

PubMed Articles [766 Associated PubMed Articles listed on BioPortfolio]

Functional outcome and social cognition in bipolar disorder: Is there a connection?

Interest in social cognition in bipolar disorder (BD) has increased considerably over the past decade, with studies highlighting major impairments, especially in mental state reasoning, even during eu...

Body Composition Changes from Infancy to 4 Years and Associations with Early Childhood Cognition in Preterm and Full-Term Children.

Infants born prematurely are at risk for neurodevelopmental complications. Early growth is associated with improved later cognition. The relationship of early proportionality and body composition with...

Improved cognitive functioning in obese adolescents after a 30-week inpatient weight loss program.

Studies linked obesity with a large number of medical conditions including decreased cognitive functioning. The relation between BMI and cognition was proven in adults, but in adolescents the results ...

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Visual Communication and Cognition in Everyday Decision-Making.

Understanding cognition and the context of decision-making should be prioritized in the design process in order to accurately anticipate the outcome for intended audiences. A thorough understanding of...

Clinical Trials [851 Associated Clinical Trials listed on BioPortfolio]

Effects of H1-Antagonist on Cognition

The purpose of this study is to determine whether histamine is involved in memory and specific processes in human cognition.

Rehabilitation of Social Cognition in Subjects With Traumatic Brain Injury

In the present study we aim to analyze the performance in a battery of social cognition tests of subjects with traumatic brain injury. On the other hand, the effectiveness of a computeriz...

Efficacy of Social Cognition Training in Schizophrenia

The term social cognition refers to how social information is processed. Individuals with schizophrenia and schizoaffective disorder have been shown to have significant deficits in social ...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

The Impact of Family Financial Support on Cognition

We have partnered with financial coaching organizations to establish what we have termed a "Medical-Financial Partnership (MFP)" that offers financial coaching to improve financial and men...

Companies [1255 Associated Companies listed on BioPortfolio]

Cognition Therapeutics Inc.

Cognition Therapeutics, Inc. is a leader in the discovery and development of small molecule therapeutics targeting the toxic proteins that cause the cognitive decline associated with Alzheimer's disea...

Cambridge Cognition Ltd

Cambridge Cognition Ltd specialises in computerised cognitive testing. Based in Cambridge, England, the company supplies products and services based on CANTAB®, the Cambridge Neuropsychological Test ...

MPI Cognition

Neurodyn Cognition Inc.

NCI is a private Canadian biotech company developing Memogain, a patented prodrug of an approved treatment for Alzheimer’s disease, galantamine (Reminyl®). Memogain’s...

Savonix

Savonix delivers the world's first fully mobile, evidence-based assessment of cognitive function. Available on Android and iOS for phone and tablet, Savonix Mobile is an accurate,...

More Information about "Cognition Therapeutics Inc." on BioPortfolio

We have published hundreds of Cognition Therapeutics Inc. news stories on BioPortfolio along with dozens of Cognition Therapeutics Inc. Clinical Trials and PubMed Articles about Cognition Therapeutics Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cognition Therapeutics Inc. Companies in our database. You can also find out about relevant Cognition Therapeutics Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record